 |
|
Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
Yeshwanter Radhakrishnan, Parikshit Duriseti, Fouad T. Chebib
Kidney Res Clin Pract. 2022;41(4):422-431. Published online 2022 Mar 29 DOI: https://doi.org/10.23876/j.krcp.21.309
|
|
Citations to this article as recorded by
 Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
Yaerim Kim, Seungyeup Han
The Korean Journal of Internal Medicine.2023; 38(3): 322. CrossRef Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
Eleftherios Gkekas, Tsz Yau Tiffany Tang, Alan Green, Han Davidson, Rachel Fraser, John A. Sayer, Shalabh Srivastava
Frontiers in Nephrology.2022;[Epub] CrossRef
|